Sol-Gel completes Phase 3 enrollment follow-up for Gorlin syndrome drug, expects data late November
Sol-Gel Technologies reported last patient last visit in its SGT-610 pivotal trial and said it holds $45.7 million in cash and securities, with runway into early 2028.
SEC filing